Breaking News

Janssen Licenses Genmab Drug

To develop and commercialize daratumumab

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Genmab and Janssen Biotech, a Johnson & Johnson company, have entered an agreement under which Janssen gains an exclusive worldwide license to develop and commercialize daratumumab (HuMax-CD38), as well as a backup human CD38 antibody. Daratumumab, a human CD38 monoclonal antibody, is in development for multiple myeloma and may have potential in other cancer indications such as acute myeloid leukemia.  Genmab will receive an upfront license fee of $55 million and Johnson & Johnson Devel...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters